Spectrum Pharmaceuticals, Inc.
SPPI · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.03 | 0.03 | -0.01 |
| FCF Yield | -14.23% | -37.86% | -22.11% | -17.13% |
| EV / EBITDA | -31.48 | -5.23 | -2.50 | -4.42 |
| Quality | ||||
| ROIC | -7.19% | -14.45% | -30.85% | -64.97% |
| Gross Margin | 93.19% | 82.28% | 0.00% | -7.69% |
| Cash Conversion Ratio | 4.28 | 2.82 | 0.82 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,953,558.20% | 2,165,266.74% | 339,021.14% | 339,021.14% |
| Free Cash Flow Growth | 15.72% | -42.76% | 23.64% | 22.69% |
| Safety | ||||
| Net Debt / EBITDA | 5.79 | 1.01 | 1.25 | 0.98 |
| Interest Coverage | -5.16 | -12.92 | -168.73 | -217.03 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.19 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,712.55 | -1,329.06 | -979,140.00 | -69,574.78 |